FY2029 Earnings Estimate for ASMB Issued By HC Wainwright

Assembly Biosciences, Inc. (NASDAQ:ASMB) – HC Wainwright issued their FY2029 earnings per share estimates for Assembly Biosciences in a report released on Monday, March 24th. HC Wainwright analyst E. Arce expects that the biopharmaceutical company will post earnings of ($12.58) per share for the year. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Assembly Biosciences’ current full-year earnings is ($6.87) per share.

Assembly Biosciences (NASDAQ:ASMB) last announced its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.75) by $0.18. The company had revenue of $7.36 million for the quarter, compared to analysts’ expectations of $7.05 million. Assembly Biosciences had a negative net margin of 144.05% and a negative return on equity of 121.46%.

Separately, StockNews.com cut Assembly Biosciences from a “buy” rating to a “hold” rating in a report on Monday.

Assembly Biosciences Trading Up 1.0 %

ASMB opened at $11.12 on Tuesday. Assembly Biosciences has a twelve month low of $10.27 and a twelve month high of $19.93. The firm has a market capitalization of $70.68 million, a PE ratio of -1.65 and a beta of 0.62. The firm’s 50-day moving average price is $12.84 and its 200 day moving average price is $15.09.

Institutional Investors Weigh In On Assembly Biosciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ASMB. Man Group plc purchased a new position in shares of Assembly Biosciences during the 4th quarter worth $309,000. B Group Inc. acquired a new position in Assembly Biosciences in the fourth quarter valued at about $799,000. Gilead Sciences Inc. purchased a new position in Assembly Biosciences during the fourth quarter worth about $34,865,000. Marshall Wace LLP increased its position in shares of Assembly Biosciences by 16.5% during the fourth quarter. Marshall Wace LLP now owns 14,823 shares of the biopharmaceutical company’s stock valued at $234,000 after acquiring an additional 2,098 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Assembly Biosciences by 44.3% during the fourth quarter. Renaissance Technologies LLC now owns 94,711 shares of the biopharmaceutical company’s stock valued at $1,495,000 after acquiring an additional 29,087 shares during the last quarter. Institutional investors and hedge funds own 19.92% of the company’s stock.

Insiders Place Their Bets

In other news, Director Michael Houghton purchased 3,202 shares of the company’s stock in a transaction dated Monday, December 30th. The stock was acquired at an average price of $15.61 per share, with a total value of $49,983.22. Following the purchase, the director now directly owns 3,202 shares in the company, valued at approximately $49,983.22. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 5.10% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.